Have you evaluated the performance of Hologic's (HOLX) international operations for the quarter ending March 2025? Given the extensive global presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!In February, I believed that Hologic, Inc. ( NASDAQ: HOLX ) started to look appealing even as organic growth was slowing. The women's health business saw pandemic related revenues run off, but rep ...

Hologic, Inc. (HOLX) reported adjusted earnings per share (EPS) of $1.03 in the second quarter of fiscal 2025, in line with the year-ago quarter’s figure. The metric surpassed the Zacks Consensus Estimate by 0.9%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The adjustments include charges and benefits related to the amortization of acquired intangible assets, restructuring and integration/consolidation costs and many others. The company’s GAAP loss per share was 8 cents in the q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOG ...

Champions of Women's Health Q2'25 Corporate Presentation Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company's strategies, positioning, resources, capabil ...

For the quarter ended March 2025, Hologic (HOLX) reported revenue of $1.01 billion, down 1.2% over the same period last year. EPS came in at $1.03, compared to $1.03 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1 billion, representing a surprise of +0.34%. The company delivered an EPS surprise of +0.98%, with the consensus EPS estimate being $1.02.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectat ...

Core Viewpoint - Hologic reported quarterly earnings of $1.03 per share, exceeding the Zacks Consensus Estimate of $1.02 per share, with revenues of $1.01 billion, surpassing expectations by 0.34% [1][2]. Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [2]. - Hologic's revenues for the quarter ended March 2025 were $1.01 billion, compared to $1.02 billion a year ago [2]. - The earnings surprise for the recent quarter was 0.98%, with the company expected to post earnings of $1.02 per share but actually reporting $1.03 [1][2]. Stock Performance - Hologic shares have declined approximately 19.3% since the beginning of the year, while the S&P 500 has decreased by 5.3% [3]. - The current Zacks Rank for Hologic is 3 (Hold), indicating expected performance in line with the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.10 on revenues of $1.03 billion, and for the current fiscal year, it is $4.27 on revenues of $4.08 billion [7]. - The outlook for the industry, particularly the Medical - Instruments sector, is favorable, ranking in the top 23% of over 250 Zacks industries [8].

Hologic (HOLX) Q2 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Michael Watts - Vice President of Investor Relations & Corporate CommunicationsStephen MacMillan - Chairman, CEO & PresidentEssex Mitchell - Chief Operating OfficerKarleen Oberton - CFOPuneet Souda - Senior MDAnthony Petrone - Managing DirectorJoseph Stringer - Managing Director, Equity ResearchLu Li - Healthcare Equity Research, DirectorCasey Woodring - Vice President - Equity ResearchAvery Kriss - Equity Research AssociateA ...

Hologic (HOLX) Q2 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Hologic's Second Quarter Fiscal twenty twenty five Earnings Conference Call. My name is Rachel, and I'm your operator for today's call. Today's conference is being recorded. All lines have been placed on mute. I would now like to introduce Mike Watts to begin the call. Speaker1 Thank you, Rachel. Good afternoon and thank you for joining Hologic's second quarter fiscal twenty twenty five earnings call. With ...

Revenue Performance - Revenue for Q2 2025 was $1,005.3 million, a decrease of 1.2% compared to the prior year, but slightly above the guidance range of $995 to $1,005 million[2]. - Total revenues for the three months ended March 29, 2025, were $1,005.3 million, a slight decrease from $1,017.8 million for the same period in 2024, representing a decline of approximately 1.5%[22]. - Consolidated GAAP revenue for the three months ended March 29, 2025, was $1,005.3 million, a slight decrease of 1.5% compared to $1,017.8 million in the prior year[29]. - Organic revenue excluding COVID-19 for the six months ended March 29, 2025, was $1,902.5 million, a decrease of 0.4% from $1,909.3 million in the same period of 2024[29]. Earnings and Profitability - GAAP diluted EPS was a loss of ($0.08), down from $0.72 in the prior year, while non-GAAP diluted EPS was $1.03, flat compared to the prior year and at the high end of guidance[2][4]. - Net income for the three months ended March 29, 2025, was a loss of $17.4 million, compared to a net income of $169.9 million for the same period in 2024, indicating a significant decrease[22]. - GAAP net income for the three months ended March 29, 2025, was a loss of $17.4 million, while the previous year showed a profit of $169.9 million[31]. - Non-GAAP net income for the six months ended March 29, 2025, was $471.5 million, compared to $480.5 million in the same period last year[31]. - Adjusted EBITDA for the six months ended March 29, 2025, was $651.9 million, compared to $650.6 million in the prior year[31]. Revenue Segmentation - Diagnostics revenue increased by 0.8% to $453.6 million, primarily driven by higher molecular diagnostics sales, while organic diagnostics sales excluding COVID-19 grew by 4.5%[2][5]. - Breast Health revenue decreased by 7.4% to $356.2 million, primarily due to lower sales of mammography capital equipment[2][5]. - Surgical revenue grew by 4.2% to $162.5 million, driven by the addition of the acquired Gynesonics business and strong international sales[2][5]. Expenses and Costs - Operating expenses for the three months ended March 29, 2025, totaled $384.3 million, an increase from $331.9 million in the same period in 2024, marking an increase of approximately 15.7%[22]. - Research and development expenses for the three months ended March 29, 2025, were $61.5 million, down from $74.6 million in the same period in 2024, representing a decrease of about 17.5%[22]. - GAAP gross margin decreased by 1,580 basis points to 37.5%, primarily due to impairment charges on intangible assets[10]. Cash Flow and Financial Position - Cash flow from operations was $169.5 million, with cash and cash equivalents at $1.43 billion at the end of the quarter[10]. - Cash and cash equivalents at the end of the period were $1,429.5 million, down from $2,180.0 million, representing a decrease of 34.4%[26]. - Total assets decreased to $8,545.1 million from $9,156.0 million, a decline of approximately 6.7%[24]. - Total current liabilities decreased to $989.7 million from $1,037.2 million, a reduction of approximately 4.6%[24]. Shareholder Actions - The company repurchased 3.0 million shares for $200 million during the quarter[2]. - Repurchases of common stock amounted to $717.3 million during the six months ended March 29, 2025, compared to $676.8 million in the prior year[26]. Guidance and Future Expectations - Full-year revenue guidance for fiscal 2025 is maintained at $4,050 - $4,100 million, while non-GAAP EPS guidance is slightly lowered to $4.15 - $4.25[7][9]. - The company expects GAAP net income per share for the quarter ending June 28, 2025, to be between $0.85 and $0.88[33]. Impairment and Charges - The impairment of intangible assets for the three months ended March 29, 2025, was $183.4 million, significantly higher than $25.9 million for the same period in 2024[22]. - The company reported an impairment charge of $220.9 million for intangible assets during the six months ended March 29, 2025[26]. Return on Investment - Adjusted Return on Invested Capital (ROIC) was 13.7%, an increase of 30 basis points compared to the prior year[10]. - Adjusted return on invested capital (ROIC) for the trailing twelve months ended March 29, 2025, was 13.7%[35]. Geographic Revenue Breakdown - Geographic revenue breakdown for the three months ended March 29, 2025: United States 74.1%, Europe 14.6%, Asia-Pacific 5.9%, and Rest of World 5.4%[38].